rewrite this title and make it good for SEORecursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Priyanka GroverJPMorgan Chase & Co, Research Division

Hi, everyone. Let’s get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I’m part of the JPMorgan Biotech team. Today, our next presenting company is Recursion and presenting on behalf of the company is CEO, Najat Khan. Thank you.

Najat KhanCEO, President & Director

Thank you, Priyanka. Good morning, everyone. It’s a pleasure to be here today. It’s a very exciting time for Recursion in terms of the recent momentum that we have and also our path ahead. So as I walk you through some of these slides today, I’m going to focus on and walk you through three specific topics. First, how we’re doubling down on translating the insights that we see into proof points that truly matter. And we’re just coming on the back of our first platform-enabled clinical proof of concept. So I’ll share more about that.

Second, we’re also going to focus on how we are surgically doubling down on certain areas in the platform that are grounded in impact. They really focus on the bottlenecks that we see in R&D. And third, we’re pairing that big ambition with discipline, discipline in our execution, discipline in our financial stewardship and also discipline in how we operate. So with that, let’s dive in.

Before I get started, please note the forward-looking slide, forward-looking statements on the slide. All right. So Recursion mission is bold and it’s also very patient-centric. Our mission remains unchanged, decoding biology to radically improve lives. Two things